GT Biopharma Inc (GTBP)

Currency in USD
1.749
+0.009(+0.52%)
Closed·
1.690-0.059(-3.40%)
·
GTBP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
GTBP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.6801.770
52 wk Range
1.6804.100
Key Statistics
Prev. Close
1.74
Open
1.77
Day's Range
1.68-1.77
52 wk Range
1.68-4.1
Volume
57.3K
Average Volume (3m)
93.42K
1-Year Change
-20.14%
Book Value / Share
-0.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GTBP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.000
Upside
+528.93%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

GT Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

GT Biopharma Inc Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Compare GTBP to Peers and Sector

Metrics to compare
GTBP
Peers
Sector
Relationship
P/E Ratio
−0.5x−3.2x−0.5x
PEG Ratio
−0.020.010.00
Price/Book
−5.6x2.6x2.6x
Price / LTM Sales
-50.5x3.3x
Upside (Analyst Target)
-183.0%41.6%
Fair Value Upside
Unlock5.1%5.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.000
(+528.93% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.33 / -0.59
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GTBP Income Statement

People Also Watch

18.80
SRPT
+4.79%
2.42
INMB
+0.83%
1.660
VOR
-16.58%
0.395
ADIL
+5.61%
0.757
TNYA
+11.16%

FAQ

What Stock Exchange Does GT Biopharma Trade On?

GT Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for GT Biopharma?

The stock symbol for GT Biopharma is "GTBP."

What Is the GT Biopharma Market Cap?

As of today, GT Biopharma market cap is 5.51M.

What Is GT Biopharma's Earnings Per Share (TTM)?

The GT Biopharma EPS (TTM) is -5.46.

From a Technical Analysis Perspective, Is GTBP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GT Biopharma Stock Split?

GT Biopharma has split 6 times.

How Many Employees Does GT Biopharma Have?

GT Biopharma has 1 employees.

What is the current trading status of GT Biopharma (GTBP)?

As of 13 Aug 2025, GT Biopharma (GTBP) is trading at a price of 1.75, with a previous close of 1.74. The stock has fluctuated within a day range of 1.68 to 1.77, while its 52-week range spans from 1.68 to 4.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.